Bertoldi Giovanni, Carraro Gianni, Ravarotto Verdiana, Di Vico Valentina, Baldini Anastasio Paola, Vitturi Nicola, Francini Francesco, Stefanelli Lucia Federica, Calò Lorenzo A
Nephrology, Dialysis and Transplantation Unit, Department of Medicine, University of Padova, Padua, Italy.
Metabolic Diseases Unit, Department of Medicine, University of Padova, Padua, Italy.
Front Nutr. 2022 Jul 8;9:924710. doi: 10.3389/fnut.2022.924710. eCollection 2022.
Enzymatic replacement therapy (ERT) is not very effective in halting the progression of Fabry disease (FD) toward cardiovascular (CV)-renal remodeling, particularly in case of late diagnosis. FD patients have increased oxidative stress (OS), critical for the induction of CV-renal remodeling. We investigated the effects of an adjuvant antioxidant treatment to ERT on OS and the possible advantages for related complications. OS was evaluated in 10 patients with FD before ERT, after 12 months of ERT, and after 6 months of adjuvant green tea (GT) to ERT by the following experiments: expression of p22; phosphorylation state of MYPT-1 and ERK 1/2 (by western blotting); and quantification of malondialdehyde (MDA) and heme oxygenase (HO)-1 levels (by ELISA). p22 and MYPT-1 phosphorylation decreased after ERT and significantly further decreased after GT. ERK 1/2 phosphorylation and MDA levels remained unchanged after ERT, but significantly decreased after GT. HO-1 significantly increased after ERT and further increased after GT. This study provides preliminary data highlighting the antioxidant effect exerted by ERT itself, further amplified by the adjuvant antioxidant treatment with GT. The results of this study provide evidence of the positive effect of early additive antioxidant treatment to reduce OS and prevent/alleviate cardio and cerebrovascular-renal complications related to OS.
酶替代疗法(ERT)在阻止法布里病(FD)向心血管(CV)-肾脏重塑进展方面效果不佳,尤其是在诊断较晚的情况下。FD患者的氧化应激(OS)增加,这对CV-肾脏重塑的诱导至关重要。我们研究了ERT辅助抗氧化治疗对OS的影响以及对相关并发症的可能益处。通过以下实验评估了10例FD患者在ERT前、ERT 12个月后以及ERT辅助绿茶(GT)6个月后的OS:p22的表达;MYPT-1和ERK 1/2的磷酸化状态(通过蛋白质印迹法);丙二醛(MDA)和血红素加氧酶(HO)-1水平的定量(通过酶联免疫吸附测定法)。ERT后p22和MYPT-1磷酸化降低,GT后显著进一步降低。ERT后ERK 1/2磷酸化和MDA水平保持不变,但GT后显著降低。ERT后HO-1显著增加,GT后进一步增加。本研究提供了初步数据,突出了ERT本身发挥的抗氧化作用,并通过GT辅助抗氧化治疗进一步放大。本研究结果提供了早期添加抗氧化治疗以降低OS并预防/减轻与OS相关的心脑血管-肾脏并发症的积极作用的证据。